PARP Inhibitor Market, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, an

PARP Inhibitor Market, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors are developed for treating several diseases, the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells, which makes these inhibitors an effective mode of treating cancers. PARP inhibitors are used to treat a subset of ovarian cancer. Currently, 3 PARP inhibitors have been approved for use in ovarian cancer patients who have undergone 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016, and Niraparib in 2017. Furthermore, several PARP inhibitors which are currently in later stages of development have shown promising results in recently released clinical trials data.
Market Dynamics
The global PARP inhibitors market is driven by product developments, increasing number of positive results, as well as availability of novel therapies in the market. Companies such as Pfizer, AstraZeneca and Tesaro, Inc. have a robust pipeline of PARP inhibitors and several ongoing trials of products are scheduled to be completed by 2022. These factors are expected to propel growth of the market over the forecast period. However, side effects associated with the drugs and drug resistance among patients are some of the factors that are expected to hamper the market growth.
Key features of the study:
This report provides in-depth analysis of the global PARP inhibitor market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global PARP inhibitor market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market
Detailed Segmentation:
Global PARP inhibitor Market, By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
Global PARP inhibitor Market, By Application:
Ovarian Cancer
Breast Cancer
Global PARP inhibitor Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global PARP inhibitor Market, By Region:
North America
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Asia Pacific
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
South Africa
Central Africa
North Africa
Company Profiles
AstraZeneca Plc.,*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Johnson & Johnson
GlaxoSmithKline plc.
Pfizer, Inc.,
Clovis Oncology Inc.
AbbVie Inc.
Bristol - Myers Squibb
Merck KGaA
Genentech, Inc.
Repare Therapeutics Inc.
Sierra Oncology, Inc.
Karyopharm Therapeutics Inc.
Ono Pharmaceutical Co. Ltd.,
Jiangsu Hengrui Medicine Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section.